Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
暂无分享,去创建一个
G. Pruneri | A. Vingiani | F. Perrone | A. Gloghini | L. Agnelli | A. Busico | D. Lorenzini | E. Tamborini | C. Volpi | G. Dagrada | I. Capone | E. Conca | D. V. Trupia
[1] G. Pruneri,et al. Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples , 2022, Exploration of targeted anti-tumor therapy.
[2] H. Feilotter,et al. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients , 2022, Molecular Diagnosis & Therapy.
[3] J. Liu,et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China , 2022, Thoracic cancer.
[4] H. Morreau,et al. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. , 2022, European journal of cancer.
[5] P. Delvenne,et al. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study , 2022, Pathobiology.
[6] H. Groen,et al. Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort , 2022, Diagnostics.
[7] Y. Bossé,et al. Performance of an RNA-Based Next-Generation Sequencing Assay for Combined Detection of Clinically Actionable Fusions and Hotspot Mutations in NSCLC , 2022, JTO clinical and research reports.
[8] J. Hechtman. NTRK insights: best practices for pathologists , 2021, Modern Pathology.
[9] D. Cappellen,et al. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. , 2021, Pathology.
[10] F. Buttitta,et al. Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network , 2021, Pathologica.
[11] E. Sokol,et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population , 2021, npj Precision Oncology.
[12] C. Antonescu,et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] I. Brčić,et al. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions , 2020, Modern Pathology.
[14] B. Hobbs,et al. Histology-agnostic drug development — considering issues beyond the tissue , 2020, Nature Reviews Clinical Oncology.
[15] Y. Kodera,et al. JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] W. Weichert,et al. Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays , 2020, Genes, chromosomes & cancer.
[17] C. Rolfo. NTRK gene fusions: a rough diamond ready to sparkle. , 2020, The Lancet. Oncology.
[18] C. Antonescu,et al. NTRK3 Overexpression in Undifferentiated Sarcomas with YWHAE and BCOR Genetic Alterations , 2020, Modern Pathology.
[19] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[20] M. Ladanyi,et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Ladanyi,et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.
[22] A. Zehir,et al. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.
[23] F. Penault-Llorca,et al. Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.
[24] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[25] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[26] P. Chi,et al. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers , 2018, Journal of Hematology & Oncology.
[27] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[28] M. Ladanyi,et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.
[29] F. Meric-Bernstam,et al. Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.
[30] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[31] A. Nakagawara,et al. Trk receptor tyrosine kinases: a bridge between cancer and neural development. , 2001, Cancer letters.
[32] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.